Cancer Biomarkers

Impact Factor
2023
3.1
CiteScore
2023
6.1

Volume

39-41, 12 issues

Latest issue

40:1 online 17 May 2024

Next issue

40:2 scheduled for June 2024

Back volumes

From volume 1, 2005

ISSN print

1574-0153

ISSN online

1875-8592
Open Access
Online Only

Aims & Scope

Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings and reviews solicited by the editor on the subject of the identification of markers associated with the prevention, detection, diagnosis, and treatment of cancer whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomic, cellular and morphologic, and genetic risk factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these risk factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation, will be accepted. Data science, artificial intelligence, radiomics, and other molecular approaches, such as bulk and single cell genomic sequence analyses for biomarkers discovery, development, and validation in reference to cancer prevention and treatment, will also be accepted.

Editorial Board

Editor-in-Chief

Sudhir Srivastava, PhD, MPH
c/o IOS Press, Inc.
6751 Tepper Drive, Clifton
USA
Fax: +1 703 830 2300
Email: CBM_peerreview at iospress.com

Associate Editors

Karen S. Anderson, MD, PhD
Biodesign Institute, Arizona State University, Tempe, AZ
USA

Liming Cheng, PhD
Tongji Medical College
China

Ajay Goel, PhD, AGAF
Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA
USA

Sam Hanash, MD, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
USA

Kazufumi Honda, PhD
Nippon Medical School, Tokyo
Japan

Li Jiang, MD, PhD
Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
China

Anna Lokshin, PhD
University of Pittsburgh Cancer Institute, Pittsburgh, PA
USA

YingYing Lu, MD, PhD
Comprehensive Liver Cancer Center
China

Lei Wang, PhD
National Center for Human Genetic Resources
China

Zhen Zhang, PhD
Johns Hopkins University School of Medicine, Baltimore, MD
USA

Lei Zheng, MD, PhD
Southern Medical University, Guangzhou
China

Statistical Editors

Ziding Feng, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA
USA

Steven J. Skates, PhD
Massachusetts General Hospital, Harvard Medical School, Boston, MA
USA

Senior Editorial Board

Timothy M. Block, PhD
Baruch S. Blumberg Institute
USA

Roger Chammas, MD, PhD
University of São Paulo, Instituto do Câncer
Brazil
    
Claudia Bessa P. Chaves, MD, PhD
Brazilian National Cancer Institute
Brazil

Alexander Borowsky, MD
UC Davis Pathology and Laboratory Medicine
USA

Arul M. Chinnaiyan, MD, PhD
University of Michigan
USA

Xiaohong Han, MD
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
China

Tony Hu, PhD
Arizona State University
USA

Aija Linē, PhD
Latvian Biomedical Research and Study Centre
Latvia

Cesar Lopez-Camarillo, PhD
Universidad Autonoma de la Ciudad de Mexico
Mexico

Patrick Nasarre, PhD
Medical University of South Carolina
USA

Norbert Nass, PhD
Brandenburg Medical School Theodor Fontane, University Hospital Brandenburg an der Havel
Germany

Cheng Peng, PhD
University of Queensland
Australia

Wenxin Qin, PhD
Shanghai Cancer Institute
China

Karin D. Rodland, PhD
Professor Emeritus
Cell, Developmental, and Cancer Biology, Oregon Health & Science University
USA
    
John Semmes, PhD
Eastern Virginia Medical School
USA

Editorial Board

Manisha Bahl, MD, MPH, FSBI
Massachusetts General Hospital, Harvard Medical School
USA

Yoganand Balagurunathan, PhD
H. Lee Moffitt Cancer Center
USA

Leonora Balaj, PhD
Massachusetts General Hospital, Harvard Medical School
USA

Wei-Min Chang, PhD
Taipei Medical University
Taiwan

Richard J. Cote, MD
Washington University in St. Louis School of Medicine
USA

Shubham Dutta, PhD
University of Massachusetts Medical School
USA

Amit Gupta, PhD
All India Institute of Medical Sciences
India

Jyoti Kode, PhD
Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre
India

Minetta C. Liu, MD
Natera
USA

Tao Liu, PhD
Pacific Northwest National Laboratory
USA

Bramanandam Manavathi, PhD
University of Hyderabad
India

Sarah Mazzilli, PhD
Boston University Chobanian & Avedisian School of Medicine
USA

Robert L. Moritz, PhD
Institute for Systems Biology
USA

Adrian O’Hara, PhD
Liverpool John Moores University
UK

John Charles Rotondo, PhD
Department of Medical Sciences, University of Ferrara
Italy

Matthew B. Schabath, PhD
H. Lee Moffitt Cancer Center & Research Institute
USA

David Sidransky, MD
Johns Hopkins University
USA

Amit Singal, MD, MS
University of Texas Southwestern Medical Center
USA

Sanford Stass, MD
University of Maryland School of Medicine
USA

Sebastien Taurin, PhD
Arabian Gulf University
Bahrain

Bechien U. Wu, MD, MPH
Center for Pancreatic Care, Division of Gastroenterology
Kaiser Permanente Los Angeles Medical Center
USA

Author Guidelines

SUBMISSION OF MANUSCRIPT

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Authors are requested to submit their manuscript electronically to the journal’s editorial management system.

The manuscript should be uploaded as one file with tables and figures included. Please use the journal's manuscript template. Acceptable file formats include Word document or LaTeX package; in case of large file size, a zip file can be uploaded.

Important note: We only accept submissions from institutional email addresses. Authors who do not have institutional email addresses will be contacted by the managing editor to provide an alternative proof of affiliation.

Required files
A .pdf file of the article is required along with the source files of the text, such as MsWord or LaTeX. If using LaTeX, please use the standard article.sty as a style file and also send a .pdf version of the LaTeX file as well as separate files of all figures (if any). See "Preparation of manuscripts" for the required file formats. LaTeX packages should be compiled into .zip or .rar files. Research articles must be accompanied by the relevant data used in the study, if these are not publicly available.

Open Access Fee
Cancer Biomarkers is moving to an Open Access model in January 2024. Submitting authors are required to agree to the article processing charge for open access publication on submission. The default pricing is US$1500 / €1500 for a CC-BY NC 4.0 license. There is also an option to select the CC BY 4.0 license for US$2150 / €2150, which is required by certain funders. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.

Waivers are available for corresponding authors from eligible countries as identified by the Research4Life project. Other authors who envisage difficulties paying the article processing charge may appeal to the editorial office to discuss waiving the charge prior to submitting their article. The corresponding author must notify the journal of their inability to pay the open access fee upon submission of the article. Appeals submitted after review will not be evaluated.

Please read full open access information here.

PREPARATION OF MANUSCRIPTS

Organization of the paper and style of presentation
Manuscripts must be written in English. Authors whose native language is not English are advised to consult a professional English language editing service or a native English speaker prior to submission.

Manuscripts should be prepared with wide margins and double spacing throughout, including the abstract, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered. However, in the text no reference should be made to page numbers; if necessary, one may refer to sections. Try to avoid the excessive use of italics and bold face.
Manuscripts should be organized in the following order:

  • Title page
  • Body of text (divided by subheadings)
  • Acknowledgements
  • Author contributions
  • References
  • Tables
  • Figure captions
  • Figures

Headings and subheadings should be numbered and typed on a separate line, without indentation.

SI units should be used, i.e., the units based on the metre, kilogramme, second, etc.

Title page
The title page should provide the following information:

  • Title (should be clear, descriptive and not too long)
  • Name(s) of author(s) without abbreviation; please indicate who is the corresponding author. Note that no authors will be added or removed post submission, unless the journal editor and all co-authors are informed and are in agreement to this change.
  • Full affiliation(s)
  • Present address of author(s), if different from affiliation
  • Complete address of the corresponding author, including tel. no., fax no., e-mail address and ORCID ID
  • Abstract
  • Keywords.

Abstract
The abstract should be clear, descriptive, self-explanatory and not longer than 200 words, it should also be suitable for publication in abstracting services.
The abstract for research papers should follow the “structured abstract” format. Section labels should be in bold uppercase letters followed by a colon, and each section will begin on a new line.
BACKGROUND:
OBJECTIVE:
METHODS:
RESULTS:
CONCLUSIONS:

Materials and Methods
Experimental subjects
When human subjects are used, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject, and that the study conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).

When experimental animals are used, the Materials and methods section must briefly but explicitly state measures which were taken to minimize pain or discomfort, e.g. type and dose of anaesthetic used. Experiments should be carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) or with the Guidelines laid down by the NIH in the US, available from the Office of Laboratory Animal Welfare, National Institutes of Health, Department of Health and Human Services, RKLI, Suite 360, MSC 7982, 6705 Rockledge Drive, Bethesda, MD 20892-7982, or online (http://grants.nih.gov/grants/olaw/olaw .htm#pol) regarding the care and use of animals for experimental procedures.

All studies using human or animal subjects should include an explicit statement in the Materials and Methods section identifying the review and approval committee for each study. Editors reserve the right to reject papers if there is doubt whether appropriate procedures have been used.

Acknowledgments
This section should contain all acknowledgments, including any funding source to the research.

Author contributions
For every author, his or her contribution to the manuscript needs to be provided using the following categories:
Conception:
Interpretation or analysis of data:
Preparation of the manuscript:
Revision for important intellectual content:
Supervision:

Please read the IOS Press authorship policy for further information.

Data Availability
Authors should include a Data Availability statement at the end of the manuscript (before the References) to describe the availability or the absence of shared data. Authors are encouraged to publicly archive their research data including, but not limited to: raw data, processed data, software, algorithms, protocols, methods, and/or materials. If the data has been shared, authors are obligated to include a link to the repository, and to reference the data. Exceptions are made if sharing data compromises ethical standards or legal requirements.

REFERENCES

Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references at the end of the manuscript in the following style:

[1] B. Newman and E.T. Liu, Perspective on BRCA1, Breast Disease 10 (1998), 3-10.
[2] D.F. Pilkey, Happy conservation laws, in: Neural Stresses, J. Frost, ed., Controlled Press, Georgia, 1995, pp. 332-391.
[3] E. Wilson, Active vibration analysis of thin-walled beams, Ph.D. Dissertation, University of Virginia, 1991.

Footnotes
Footnotes should only be used if absolutely essential. In most cases it is possible to incorporate the information in the text.

If used, they should be numbered in the text, indicated by superscript numbers and kept as short as possible.

Tables
Number as Table 1, Table 2 etc., and refer to all of them in the text.
Each table should be provided on a separate page of the manuscript. Tables should not be included in the text.
Each table should have a brief and self-explanatory title.
Column headings should be brief, but sufficiently explanatory. Standard abbreviations of units of measurement should be added between parentheses.
Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.
Any explanations essential to the understanding of the table should be given in footnotes at the bottom of the table.

Figures
Number figures as Fig. 1, Fig. 2, etc. and refer to all of them in the text.

Each figure should be provided on a separate sheet. Figures should not be included in the text.

Color figures can be included in the print version, provided the cost of their reproduction is paid for by the author. The online version has no extra charges for color figures.

For the file formats of the figures please take the following into account:
- Line art should be have a minimum resolution of 600 dpi, save as EPS or TIFF
- Grayscales (incl. photos) should have a minimum resolution of 300 dpi (no lettering), or 500 dpi (when there is lettering); save as tiff
- Do not save figures as JPEG, this format may lose information in the process
- Do not use figures taken from the Internet, the resolution will be too low for printing
- Do not use color in your figures if they are to be printed in black & white, as this will reduce the print quality (note that in software often the default is color, you should change the settings)
- For figures that should be printed in color, please send a CMYK encoded EPS or TIFF

Figures should be designed with the format of the page of the journal in mind. They should be of such a size as to allow a reduction of 50%.

On maps and other figures where a scale is needed, use bar scales rather than numerical ones, i.e., do not use scales of the type 1:10,000. This avoids problems if the figures need to be reduced.

Each figure should have a self-explanatory caption. The captions to all figures should be typed on a separate sheet of the manuscript.

Photographs are only acceptable if they have good contrast and intensity.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Article sharing
Authors of journal articles are permitted to self-archive and share their work through institutional repositories, personal websites, and preprint servers. Authors have the right to use excerpts of their article in other works written by the authors themselves, provided that the original work is properly cited. The consent for sharing an article, in whole or in part, depends on the version of the article that is shared, where it is shared, and the copyright license under which the article is published. Please refer to the IOS Press Article Sharing Policy for further information.

Quoting from other publications
Authors, when quoting from someone else's work or when considering reproducing figures or tables from a book or journal article, should make sure that they are not infringing a copyright. Although in general authors may quote from other published works, permission should be obtained from the holder of the copyright if there will be substantial extracts or reproduction of tables, plates, or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

PROOFS AND PRE-PRESS

The corresponding author will receive a PDF proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

The corrected proof is published online in the journal’s pre-press module. This is not the final version. When the article is published in an issue, the final published version replaces the pre-press file. Pre-press articles are fully citable by using their DOI number.

PURCHASES

The corresponding author of a contribution to the journal will receive a complimentary PDF Author’s Copy of the article, unless otherwise stated. An order form for reprints or additional journal copies will be provided along with the PDF proof.

If you wish to order reprints of an earlier published article, please contact the publisher for a quotation using the contact form.

KUDOS

Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.

HOW TO PROMOTE YOUR WORK

Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.

 

Please visit the IOS Press Authors page for further information.

 

Abstracted/Indexed in

Academic Search
CAB Abstracts
Cabell's Guide or Directory
Chemical Abstracts Service (CAS)
Elsevier BIOBASE
Embase
EMBIO
MEDLINE
Microsoft Academic Search
Prous Science Integrity
PubMed
PubsHub
SciVerse Scopus
Ulrich's Periodicals Directory
Web of Science: Biological Abstracts
Web of Science: BIOSIS Previews
Web of Science: Journal Citation Reports/Science Edition
Web of Science: Science Citation Index Expanded (SciSearch®)

Open Access

Gold open access pricing
From 2024 onwards Cancer Biomarkers has moved from its previous hybrid publication model to a true gold open access journal. Authors of accepted papers will be required to pay an open access fee of US$1500 / €1500 (ex. VAT if applicable) to publish under the CC BY-NC 4.0 license on acceptance for publication. Publishing under the CC BY 4.0 license is available at US$2150 / €2150 (ex. VAT if applicable). After an article is accepted for publication, the corresponding author will be informed regarding the open access options during the production stages. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.

Waivers are available for corresponding authors from eligible countries as identified by the Research4Life project. Other authors who envisage difficulties paying the article processing charge may appeal to the editorial office to discuss waiving the charge prior to submitting their article. The corresponding author must notify the journal of their inability to pay the open access fee upon submission of the article. Appeals submitted after review will not be evaluated.

Articles published behind a paywall in the pre-2024 volumes are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library, even after final publication. This means that the current version will be made freely available to anyone worldwide, indefinitely, under a Creative Commons license. Authors can purchase open access at any time through the order form link in their decision letter.

Green open access
Authors who did not make use of the gold open access option pre-2024 may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.

PubMedCentral deposits
This journal deposits all open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library. If an author chooses to publish their paper with open access then the publisher will deposit the article in PMC upon publication.

Peer Review Policy

Cancer Biomarkers is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.

After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.

Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work. They might consider inviting the reviewers suggested by the author or not. Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).

As a standard policy, decisions are based on three reviews, in some specific circumstances a minimum of two reviews may be deemed sufficient to make a decision on a paper. The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.

Reviewers are asked to judge a paper on at least:

  • Significance to field
  • Relevance to journal
  • Methodology
  • Data analysis
  • Literature review
  • Writing style/clarity

Based on the received reviews the handling editor will propose to the Editor-in-Chief a recommendation:

  1. Accept
  2. Minor revisions required
  3. Major revisions required
  4. Reject

They mean the following:

  1. The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
  2. The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors have been addressed satisfactorily. The revised manuscript will be examined by the Editor in Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  3. The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  4. The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.

Authors are notified by the Editor-in-Chief, whose decision is final.

Do you Wish to Receive Updates? – If you would like to receive news updates about Cancer Biomarkers (CBM), let us know by signing up at: tiny.cc/CBMsignup. To view the latest mailing, click here.

Call for Papers Announcement (Aug 2022) – A special issue is planned on “Single-Cell Proteomics Workflow for Cancer Research” (Guest Editor: Tao Liu, PhD) to showcase perspectives or research on state-of-the-art single-cell proteomics methods, platforms, computational tools, and relevant applications in cancer. Discover more here! (deadline for submission: Aug 1, 2023)

Special Issue Published – The latest special issue in Vol.33, Iss.4 (Apr 2022), on the topic "Collaboration Between US and Japan for the Early Detection of Cancer" (guest editor: Kazufumi Honda), is openly available until Oct 31, 2022. Read the issue newsletter here!

Presentation at IOS Press Symposium – The journal's Editor-in-Chief Sudhir Srivastava was one of the esteemed scholars who participated in the IOS Press 35th anniversary symposium on Mar 31, 2022 in Amsterdam. The focus of his presentation was the journal's history, current developments, and prospects, as well as more broadly the area of biomarkers research. Discover more here!

AI Special Issue – Discover this special issue on the topic "Applications of Artificial Intelligence in Biomarker Research" (guest editor: Karin Rodland, PhD) in Vol.33, Iss.2 (Feb 2022), which was openly available until Aug 31, 2022. View background and testimonials here!

Journal Impact Factor – The latest Journal Citation Reports sees CBM's Impact Factor changing to 3.828 (Source Clarivate, 2022). The journal is listed in the Oncology category of Science Citation Index Expanded (SCIE).

Latest Articles

Discover the contents of the latest journal issue:

Deep learning approaches for breast cancer detection in histopathology images: A review
Biju V G, Lakshmi Priya C V, Vinod B R, Sivakumar Ramachandran

Identification of Hub genes with prognostic values in colorectal cancer by integrated bioinformatics analysis
Ting Li, Shan Li, Yan-Qing Shi, Bin-Jie Xu, Yu-Yong Deng, Xu-Guang Sun

PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway
Baogui Wang, Sixu Zhou, Yingying Wei, Peiru Dai, Yan Chen, Yingyi Xiao, Hongmei Xia, Chunlin Chen, Weihua Yin

Long non-coding RNAs PTENP1, GNG12-AS1, MAGI2-AS3 and MEG3 as tumor suppressors in breast cancer and their associations with clinicopathological parameters
Eva Jandáková, Luděk Záveský, Vít Weinberger, Luboš Minář, Milada Kohoutová, Ondřej Slanař

Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer
Zhongqi Pang, Yang Liu, Jianshe Wang, Jinfeng Wang, Bo Ji, Yidan Xu, Jiaxin He, Lu Zhang, Yansong Han, Linkun Shen, Wanhai Xu, Minghua Ren

Sustainable Development Goals

The content of this journal relates to SDG:

sdg symbolsdg symbolsdg symbol

Visit the SDG page for more information.

Supporting Diversity and Inclusion

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

CBM geo data visual on dark blue background

More information will be available in due course. Check the SDGs page for updates.  

CBM AI-focused special issue burgandy banner

CBM news signup long banner